Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)13-21
Number of pages9
JournalHealth technology assessment
Volume15
Issue numberSuppl. 1
Publication statusPublished - May 2011

Cite this